New endogenous anti-inflammatory and proresolving lipid mediators: Implications for rheumatic diseases

Nature Clinical Practice Rheumatology

Volumn 3, Issue 10, 2007, Pages 570-579

  Yacoubian, Stephanie ^a   Serhan, Charles N ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BRAIN PROTEIN; CD59 ANTIGEN; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; FISH OIL; GLUCOCORTICOID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXIN; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN E2; RESOLVIN; RESOLVIN D1; RESOLVIN D2; RESOLVIN D3; RESOLVIN D4; RESOLVIN E1; RESOLVIN E2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; DRUG MEGADOSE; HOST RESISTANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIPID METABOLISM; LOW DRUG DOSE; MACROPHAGE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCAR FORMATION; SIGNAL TRANSDUCTION; STEREOSPECIFICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; FATTY ACIDS, OMEGA-3; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LEUKOTRIENES; LIPOXINS; PROSTAGLANDINS; RHEUMATIC DISEASES;

EID: 34848843481     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0616     Document Type: Review

References (67)

1. Samuelsson B et al. (1987) Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237: 1171-1176
2. Vane JR (1982) Adventures and excursions in bioassay: The stepping stones to prostacyclin. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, 181-206. Stockholm: Almqvist & Wiksell
3. Serhan CN and Savill J (2005) Resolution of inflammation: The beginning programs the end. Nat Immunol 6: 1191-1197
4. 4 are potent stimuli for human monocyte migration and adhesion: Selective inactivation by dehydrogenation and reduction. J Exp Med 183: 137-146
5. Levy BD et al. (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2: 612-619
6. Serhan CN et al. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204
7. Serhan CN et al. (2002) Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J Exp Med 196 1025-1037
8. Hong S et al. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: Autacoids in anti-inflammation. J Biol Chem 278 14677-14687
9. Serhan CN et al. (2006) Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 176: 1848-1859
10. Marcheselli VL et al. (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278: 43807-43817
11. Lukiw WJ et al. (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115: 2774-2783
12. Cotran RS et al. (Eds, 1999) Robbins Pathologic Basis of Disease. Philadelphia: WB Saunders
13. Serhan CN et al. (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21: 325-332
14. Rajakariar R et al. (2006) COX-2 in inflammation and resolution. Mol Interv 6: 199-207
15. Kapoor M et al. (2007) Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: A time course study. Prostaglandins Leukot Essent Fatty Acids 76: 103-112
16. Serhan CN (Ed., 2005) Special issue on lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 73: 139-321
17. Godson C et al. (2000) Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663-1667
18. Bannenberg GL et al. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174: 4345-4355
19. Weissmann G (2004) Pathogenesis of rheumatoid arthritis. J Clin Rheumatol 10 (3 Suppl): S26-S31
20. 4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 101: 15178-15183
21. 4 stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 185: 1693-1704
22. 4 is required for inflammatory arthritis. J Exp Med 203: 837-842
23. Devchand PR et al. (2003) Human ALX receptor regulates neutrophil recruitment in transgenic mice: Roles in inflammation and host-defense. FASEB J 17: 652-659
24. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: A role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39: 4761-4768
25. Schottelius AJ et al. (2002) An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J Immunol 169: 7063-7070
26. 4 analogs. Prostaglandins Leukot Essent Fatty Acids 73: 245-250
27. Thomas E et al. (1995) Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm Res 44: 121-124
28. Dave M et al. (2003) Differential expression of lipoxin and lipoxin receptors in osteoarthritis cartilage: A functional genomic analysis. J Leukocyte Biol (Suppl): 18
29. Sodin-Semrl S et al. (2004) Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes. Int J Immunopathol Pharmacol 17: 15-25
30. Sodin-Semrl S et al. (2000) Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 164: 2660-2666
31. Rodgers K et al. (2005) Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol 167: 683-694
32. Nascimento-Silva V et al. (2005) Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 289: C557-C563
33. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354: 447-455
34. Arita M et al. (2005) Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722
35. Arita M et al. (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 102: 7671-7676
36. 4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178: 3912-3917
37. Tjonahen E et al. (2006) Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol 13: 1193-1202
38. Gronert K et al. (2005) A role forthe mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 280: 15267-15278
39. Sun Y-P et al. (2007) Resolvin D1 and its aspirin-triggered 17R epimer: Stereochemical assignments, anti-inflammatory properties and enzymatic inactivation. J Biol Chem 282: 9323-9334
40. Hasturk H et al. (2006) RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J 20: 401-403
41. Mukherjee PK et al. (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101: 8491-8496
42. González-Périz A et al. (2006) Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 20: 2537-2539
43. Duffield JS et al. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177: 5902-5911
44. Ariel A et al. (2006) Apoptotic neutrophils and T cells sequester chemokines during immune response resolution via modulation of CCR5 expression. Nat Immunol 7: 1209-1216
45. Hong S et al. (2005) Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins: Mediator lipidomic analysis. Prostaglandins Other Lipid Mediat 78: 107-116
46. 2 synthases. Clin Immunol 119: 229-240
47. Robinson DR et al. (1979) Prostaglandins and their regulation in rheumatoid inflammation. Ann NY Acad Sci 332: 279-294
48. Sperling RI et al. (1987) Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum 30: 988-997
49. Shichikawa K et al. (1981) A longitudinal population survey of rheumatoid arthritis in a rural district in Wakayama. Ryumachi 21 (Suppl): 35-43
50. Geusens P et al. (1994) Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 37: 824-829
51. Leeb BF et al. (2006) Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study. Lipids 41: 29-34
52. James MJ et al. (2003) Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: Issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukot Essent Fatty Acids 68: 399-405
53. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83 (suppl): S1505-S1519
54. Mercado FB et al. (2003) Inter-relationships between rheumatoid arthritis and periodontal disease: A review. J Clin Periodontol 30: 761-772
55. Bhattacharya A et al. (2005) Inhibition of osteoporosis in autoimmune disease prone MRL.Mpj-Fas(lpr) mice by n-3 fatty acids. J Am Coll Nutr 24: 200-209
56. Han C et al. (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33: 2167-2172
57. Cleland LG et al. (2006) Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J Rheumatol 33: 1973-1979
58. Sacks FM and Campos H (2006) Editorial: Polyunsaturated fatty acids, inflammation, and cardiovascular disease: Time to widen our view of the mechanisms. J Clin Endocrinol Metab 91: 398-400
59. Hudert CA et al. (2006) Transgenic mice rich in endogenouse n-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 103: 11276-11281
60. McGettigan P and Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1653-1656
61. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285
62. De Bandt M et al. (2006) Tumour necrosis factor alpha blockade and the risk of vasculitis. Ann Rheum Dis 65: 1534-1535
63. Hochman D and Wolff B (2006) Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296: 2203
64. Svensson CI et al. (2007) Lipoxins and aspirin-triggered lipoxin stop inflammatory pain processing. J Exp Med 204: 245-252
65. Jozsef L et al. (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 99: 13266-13271
66. Mitchell S et al. (2002) Lipoxins, aspirin-triggered epilipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13: 2497-2507
67. Levy BD et al. (2007) Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J Immunol 178: 496-502